Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
revance
Overview
Revance Therapeutics, Inc. is a commercial-stage biotechnology company focused on innovative aesthetic and therapeutic offerings. Primarily operating in the aesthetic and therapeutic neuromodulator market, Revance's core focus is on developing and commercializing differentiated, long-acting neuromodulators, exemplified by their DAXXIFY (daxibotulinumtoxinA-lanm) injection for glabellar lines. With FDA approval secured, Revance is actively disrupting the aesthetics landscape by challenging the dominance of established players like Botox, and expanding into the therapeutic market, with plans for expanding into other aesthetic and therapeutic indications. This positions Revance as a competitive player with potential for sustained growth and market share gain in the rapidly expanding neuromodulator market.
revance's headcount breakdown by department
| Department | HeadCount |
|---|---|
Administrative | 7 |
Consulting | 88 |
Service | 7 |
Design | 7 |
Education | 7 |
Revance's department distribution suggests a company transitioning from a purely R&D-focused organization to one heavily invested in commercialization and market penetration. The presence of a substantial 'Other Department' (111 employees) likely encompasses crucial functions like regulatory affairs, quality assurance, and potentially manufacturing support, which are essential in the highly regulated biopharmaceutical industry. A significant 'Consulting' team (88 employees) likely indicates the ongoing use of external expertise to support market access, reimbursement strategies, and potentially clinical trial management. A dedicated 'Research' team of 40 employees signifies continued investment in innovation and future product development. Crucially, the emphasis on commercial functions is evident through a 'Sales' team of 35, supported by 'Marketing' (13 employees) and 'Customer Service' (7 employees), signifying the company's focus on driving product adoption and revenue generation. The 'Technical' team of 34 implies in-house capabilities for aspects of manufacturing and/or process development although some activities may be outsourced. The presence of a 'Medical Affairs' team (11 employees) underscores the commitment to scientific integrity, physician education, and post-market surveillance, reflecting a company-driven, medically-led commercial approach. The relatively lean 'Administrative,' 'HR,' and 'Finance' functions demonstrate efficient resource allocation, especially considering the company's commercialization phase. The workforce composition shows a balanced approach, supporting both ongoing innovation and effective market access, typical of a biotech company in its commercial growth stage.
revance's employees by locations
Employee Count by Country
Total: 459 employees
Revance's geographic footprint is predominantly concentrated in the United States, with 448 of its 669 employees based there. This heavily domestic focus reflects the strategic priority of the U.S. market for its initial commercial launch of DAXXIFY and development of their therapeutic pipeline. The limited presence in other countries—including Europe (France, UK), Latin America (Uruguay, Argentina, Brazil), and Asia (China, India)—suggests a phased approach to global expansion. These locations likely support early-stage market research, clinical trial activities, and potential future market entry. For example, the presence in Argentina and Uruguay might be due to certain tax or regulatory advantages for conducting research. The small team in China could be linked to early exploration of the Chinese aesthetics market, which is experiencing rapid growth. Overall, Revance's geographic strategy centers around establishing a strong foothold in the U.S. market before significantly investing in global expansion, which is a common approach in the biopharmaceutical industry due to regulatory complexities and market-specific dynamics. This controlled international presence suggests a calculated approach, leveraging remote expertise and strategic partnerships to support future growth in key global markets.
Want to stay ahead of revance's org changes?
Get alerts when hiring spikes or teams shift focus
Track changes vs. competitors
Spot warm GTM signals early